株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

白斑の世界市場:治療薬・主要企業・臨床研究・課題

Global Vitiligo Market, Patients By Countries (USA, UK, France, Germany, Italy, India, China, Japan), Drugs (ARN-4079, ATI-502, AX-1602, BOS-47, CCP-070, Cerdulatinib (RVT-502), HuABC-2, & Others) Companies, Clinical Study, Growth Drivers, Challenges

発行 Renub Research 商品コード 756444
出版日 ページ情報 英文 100 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=109.54円で換算しております。
Back to Top
白斑の世界市場:治療薬・主要企業・臨床研究・課題 Global Vitiligo Market, Patients By Countries (USA, UK, France, Germany, Italy, India, China, Japan), Drugs (ARN-4079, ATI-502, AX-1602, BOS-47, CCP-070, Cerdulatinib (RVT-502), HuABC-2, & Others) Companies, Clinical Study, Growth Drivers, Challenges
出版日: 2018年12月10日 ページ情報: 英文 100 Pages
概要

世界におけ白斑市場の規模は、2024年までに24億米ドルに達すると予測されています。

当レポートでは、世界の白斑治療薬市場について調査し、世界市場における患者人口・患者人口シェア、および主要各国におけるの患者人口と市場規模、市場成長の促進要因と課題、研究開発動向、および主要企業のプロファイルなどをまとめています。

第1章 イントロダクション

第2章 分析手法

第3章 エグゼクティブサマリー

第4章 世界の白斑患者人口 & 市場

  • 白斑患者人口
  • 白斑市場

第5章 シェア:世界の白斑患者人口 & 市場

  • 白斑患者人口シェア
  • 白斑市場シェア

第6章 米国

  • 白斑患者人口
  • 白斑市場

第7章 英国

第8章 フランス

第9章 ドイツ

第10章 イタリア

第11章 インド

第12章 中国

第13章 日本

第14章 パイプライン薬

  • ARN-4079
  • ATI-502
  • AX-1602
  • BOS-475
  • CCP-070
  • Cerdulatinib (RVT-502)
  • HuABC-2
  • Abatacept
  • Topical Ruxolitinib
  • VLRX-001

第15章 臨床研究

第16章 成長促進要因

  • 美的魅力の重要性の高まり
  • 世界の白斑の日

第17章 世界の白斑市場:課題

  • 皮膚科医の不足
  • 利用可能な治療はあまり効果的ではない

第18章 AXIM Biotechnologies, Inc.

第19章 Incyte Corporation

第20章 Bristol-Myers Squibb

第21章 Clinuvel Pharmaceuticals Ltd

図表

List of Figures:

Figure 4 1: Global - Vitiligo Patients Population (Thousand), 2012 - 2017

Figure 4 2: Global - Forecast for Vitiligo Patients Population (Thousand), 2018 - 2024

Figure 4 3: Global - Vitiligo Market (Million US$), 2012 - 2017

Figure 4 4: Global - Forecast for Vitiligo Market (Million US$), 2018 - 2024

Figure 5 1: Global - Vitiligo Patients Population Share (Percent), 2012 - 2017

Figure 5 2: Global - Forecast for Vitiligo Patients Population Share (Percent), 2018 - 2024

Figure 5 3: Global - Vitiligo Market Share (Percent), 2012 - 2017

Figure 5 4: Global - Forecast for Vitiligo Market Share (Percent), 2018 - 2024

Figure 6 1: United States - Vitiligo Patients Population (Thousand), 2012 - 2017

Figure 6 2: United States - Forecast for Vitiligo Patients Population (Thousand), 2018 - 2024

Figure 6 3: United States - Vitiligo Market (Million US$), 2012 - 2017

Figure 6 4: United States - Forecast for Vitiligo Market (Million US$), 2018 - 2024

Figure 7 1: United Kingdom - Vitiligo Patients Population (Thousand), 2012 - 2017

Figure 7 2: United Kingdom - Forecast for Vitiligo Patients Population (Thousand), 2018 - 2024

Figure 7 3: United Kingdom - Vitiligo Market (Million US$), 2012 - 2017

Figure 7 4: United Kingdom - Forecast for Vitiligo Market (Million US$), 2018 - 2024

Figure 8 1: France - Vitiligo Patients Population (Thousand), 2012 - 2017

Figure 8 2: France - Forecast for Vitiligo Patients Population (Thousand), 2018 - 2024

Figure 8 3: France - Vitiligo Market (Million US$), 2012 - 2017

Figure 8 4: France - Forecast for Vitiligo Market (Million US$), 2018 - 2024

Figure 9 1: Germany - Vitiligo Patients Population (Thousand), 2012 - 2017

Figure 9 2: Germany - Forecast for Vitiligo Patients Population (Thousand), 2018 - 2024

Figure 9 3: Germany - Vitiligo Market (Million US$), 2012 - 2017

Figure 9 4: Germany - Forecast for Vitiligo Market (Million US$), 2018 - 2024

Figure 10 1: Italy - Vitiligo Patients Population (Thousand), 2012 - 2017

Figure 10 2: Italy - Forecast for Vitiligo Patients Population (Thousand), 2018 - 2024

Figure 10 3: Italy - Vitiligo Market (Million US$), 2012 - 2017

Figure 10 4: Italy - Forecast for Vitiligo Market (Million US$), 2018 - 2024

Figure 11 1: India - Vitiligo Patients Population (Thousand), 2012 - 2017

Figure 11 2: India - Forecast for Vitiligo Patients Population (Thousand), 2018 - 2024

Figure 11 3: India - Vitiligo Market (Million US$), 2012 - 2017

Figure 11 4: India - Forecast for Vitiligo Market (Million US$), 2018 - 2024

Figure 12 1: China - Vitiligo Patients Population (Thousand), 2012 - 2017

Figure 12 2: China - Forecast for Vitiligo Patients Population (Thousand), 2018 - 2024

Figure 12 3: China - Vitiligo Market (Million US$), 2012 - 2017

Figure 12 4: China - Forecast for Vitiligo Market (Million US$), 2018 - 2024

Figure 13 1: Japan - Vitiligo Patients Population (Thousand), 2012 - 2017

Figure 13 2: Japan - Forecast for Vitiligo Patients Population (Thousand), 2018 - 2024

Figure 13 3: Japan - Vitiligo Market (Million US$), 2012 - 2017

Figure 13 4: Japan - Forecast for Vitiligo Market (Million US$), 2018 - 2024

Figure 14 1: Vitiligo Pipe Line Drug - ARN-4079 Status (2018)

Figure 14 2: Vitiligo Pipe Line Drug - ATI-502 Status (2018)

Figure 14 3: Vitiligo Pipe Line Drug - AX-1602 Status (2018)

Figure 14 4: Vitiligo Pipe Line Drug - BOS-475 Status (2018)

Figure 14 5: Vitiligo Pipe Line Drug - CCP-070 Status (2018)

Figure 14 6: Vitiligo Pipe Line Drug - Cerdulatinib (RVT-502) Status (2018)

Figure 14 7: Vitiligo Pipe Line Drug - HuABC-2 Status (2018)

Figure 14 8: Vitiligo Pipe Line Drug - Abatacept Status (2018)

Figure 14 9: Vitiligo Pipe Line Drug - Topical Ruxolitinib Status (2018)

Figure 14 10: Vitiligo Pipe Line Drug - VLRX-001 Status (2018)

Figure 18 1: Axim Biotechnologies, Inc - Global Sales (US$), 2015 - 2017

Figure 18 2: Axim Biotechnologies, Inc - Forecast for Global Sales (US$), 2018 - 2024

Figure 19 1: Incyte Corporation - Global Sales (Million US$), 2012 - 2017

Figure 19 2: Incyte Corporation - Forecast for Global Sales (Million US$), 2018 - 2024

Figure 20 1: Bristol-Myers Squibb - Global Sales (Million US$), 2012 - 2017

Figure 20 2: Bristol-Myers Squibb - Forecast for Global Sales (Million US$), 2018 - 2024

Figure 21 1: Clinuvel Pharmaceuticals Limited - Global Sales (Thousand US$), 2013 - 2017

Figure 21 2: Clinuvel Pharmaceuticals Limited - Forecast for Global Sales (Thousand US$), 2018 - 2024

List of Tables:

  • Table 15-1: Global - Vitiligo Market Clinical Study, 2018
目次

Title:
Global Vitiligo Market
Patients By Countries (United States, United Kingdom, France, Germany, Italy, India, China, Japan), Drugs (ARN-4079, ATI-502, AX-1602, BOS-47, CCP-070, Cerdulatinib (RVT-502), HuABC-2, Abatacept, Topical Ruxolitinib, VLRX-001) Companies (AXIM Biotechnologies, Incyte Corporation, Bristol-Myers Squibb, Clinuvel Pharmaceuticals), Clinical Study, Growth Drivers, Challenges.

Vitiligo is a long-term skin disease in which patches of the skin lose their color. The skin patches affected by the disease Vitiligo become white. This happens because melanocytes within the skin die off. The skin pigmentation, melanin, due to which skin has its color, protection from sun UV rays this all happens because of melanocytes cells. Growing per capita healthcare expenditure, improving healthcare infrastructure in developing countries, growing diseases awareness and expected approval of Vitiligo drugs are some of the driving force for the growth of this market. However, shortage of dermatologists and available treatments having longer duration of times are major challenges for the growth of this market. According to Renub Research global Vitiligo market will be US$ 2.4 Billion by the year 2024.

Vitiligo disease prevalence varies between race, regions and countries. It is expected that overall prevalence fall between 1-2 percent of the total population. Although Vitiligo disease can arise at any age, it mostly occurs to young and middle age people. At present globally over 21 Million people has suffered from this diseases. There are number of drugs manufactures working for Vitiligo drugs development across various parts of the globe such as AXIM Biotechnologies, Boston Pharmaceutical, Castle Creek Pharma, Dermavant Sciences, JN Biosciences, Bristol-Myers Squibb, Incyte Corporation, Clinuvel Pharmaceuticals etc. and their Vitiligo drugs development are in various stages.

Renub Research report titled "Global Vitiligo Market, Patients By Countries (United States, United Kingdom, France, Germany, Italy, India, China, Japan), Drugs (ARN-4079, ATI-502, AX-1602, BOS-47, CCP-070, Cerdulatinib (RVT-502), HuABC-2, Abatacept, Topical Ruxolitinib, VLRX-001) Companies (AXIM Biotechnologies, Incyte Corporation, Bristol-Myers Squibb, Clinuvel Pharmaceuticals), Clinical Study, Growth Drivers, Challenges" provides a complete analysis of global vitiligo drugs market.

India and China are Key Contributors in the Global Vitiligo Patient Population

Vitiligo patient's population is growing across all parts of the world. Patient's growth rates varies in the countries covered in the report United States, United Kingdom, France, Germany, Italy, India, China and Japan. India and China are key contributors in the global vitiligo patient population.

Vitiligo Pipe Line Drugs are Key Strength for this Market Place

In the global vitiligo market, vitiligo pipe line drugs will play the major role for the growth of this market. At present several drugs such as ARN-4079, ATI-502, AX-1602, BOS-47, CCP-070, Cerdulatinib (RVT-502), HuABC-2, Abatacept, Topical Ruxolitinib, VLRX-001 etc. are in preclinical, IND, Phase I, Phase II and Phase III stage.

Key Drugs Development Companies are working in this Market Place

Key drugs development companies are working in this market place across various parts of the globe such as AXIM Biotechnologies, Boston Pharmaceutical, Castle Creek Pharma, Dermavant Sciences, JN Biosciences, Bristol-Myers Squibb, Incyte Corporation, Clinuvel Pharmaceuticals etc.

Segments - Global Vitiligo Market:

  • Vitiligo Patients Population
  • Vitiligo Market

Countries - Global Vitiligo Market:

  • United States
  • United Kingdom
  • France
  • Germany
  • Italy
  • India
  • China
  • Japan

Global Vitiligo Market - Drugs Profile Covered:

  • ARN-4079
  • ATI-502
  • AX-1602
  • BOS-47
  • CCP-070
  • Cerdulatinib (RVT-502)
  • HuABC-2
  • Abatacept
  • Topical Ruxolitinib
  • VLRX-001

Companies Covered

  • AXIM Biotechnologies
  • Incyte Corporation
  • Bristol-Myers Squibb
  • Clinuvel Pharmaceuticals

Each Company Covered in this Report has Following Details:

  • Company Overview
  • Company Initiatives
  • Financial Insight

Table of Contents

1. Introduction

  • 1.1 Market Definition

2. Research Methodology

3. Executive Summary

4. Global Vitiligo Patient Numbers & Market

  • 4.1 Vitiligo Patients Numbers
  • 4.2 Vitiligo Market

5. Share - Global Vitiligo Patient Numbers & Market

  • 5.1 Vitiligo Patient Numbers Share
  • 5.2 Vitiligo Market Share

6. United States

  • 6.1 Vitiligo Patient Numbers
  • 6.2 Vitiligo Market

7. United Kingdom

  • 7.1 Vitiligo Patient Numbers
  • 7.2 Vitiligo Market

8. France

  • 8.1 Vitiligo Patient Numbers
  • 8.2 Vitiligo Market

9. Germany

  • 9.1 Vitiligo Patient Numbers
  • 9.2 Vitiligo Market

10. Italy

  • 10.1 Vitiligo Patient Numbers
  • 10.2 Vitiligo Market

11. India

  • 11.1 Vitiligo Patient Numbers
  • 11.2 Vitiligo Market

12. China

  • 12.1 Vitiligo Patient Numbers
  • 12.2 Vitiligo Market

13. Japan

  • 13.1 Vitiligo Patient Numbers
  • 13.2 Vitiligo Market

14. Vitiligo Pipe Line Drugs

  • 14.1 ARN-4079
  • 14.2 ATI-502
  • 14.3 AX-1602
  • 14.4 BOS-475
  • 14.5 CCP-070
  • 14.6 Cerdulatinib (RVT-502)
  • 14.7 HuABC-2
  • 14.8 Abatacept
  • 14.9 Topical Ruxolitinib
  • 14.10 VLRX-001

15. Clinical Study of Vitiligo Market

16. Growth Drivers

  • 16.1 Growing Importance of Aesthetic Appeal
  • 16.2 World Vitiligo Day: Increases Vitiligo Awareness

17. Global Vitiligo Market - Challenges

  • 17.1 Shortage of Dermatologists
  • 17.2 Available Treatments are Not Much Effective

18. AXIM Biotechnologies, Inc.

  • 18.1 Company Overview
  • 18.2 Initiatives
    • 18.2.1 Point 1
    • 18.2.2 Point 2
    • 18.2.3 Point 3
  • 18.3 Financial Insight

19. Incyte Corporation

  • 19.1 Company Overview
  • 19.2 Initiatives
    • 19.2.1 Point 1
    • 19.2.2 Point 2
  • 19.3 Financial Insight

20. Bristol-Myers Squibb

  • 20.1 Company Overview
  • 20.2 Initiatives
    • 20.2.1 Point 1
    • 20.2.2 Point 2
  • 20.3 Financial Insight

21. Clinuvel Pharmaceuticals Ltd

  • 21.1 Company Overview
  • 21.2 Company Initiatives
    • 21.2.1 Point 1
    • 21.2.2 Point 2
  • 21.3 Financial Insight
Back to Top